Research programme: inflammation, pain and arthritis therapeutics - InMed Pharmaceuticals

Drug Profile

Research programme: inflammation, pain and arthritis therapeutics - InMed Pharmaceuticals

Alternative Names: CTI-091; Delta-9-tetrahydrocannabinol - InMed Pharmaceuticals; Dronabinol - InMed Pharmaceuticals

Latest Information Update: 25 Nov 2016

Price : $50

At a glance

  • Originator Cannabis Technologies
  • Developer InMed Pharmaceuticals; University of British Columbia
  • Class Cannabinoids
  • Mechanism of Action Gene expression modulators; Immunomodulators; Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Arthritis; Inflammation; Joint disorders; Musculoskeletal pain; Pain

Most Recent Events

  • 26 Sep 2016 Pharmacodynamics data from a preclinical trial in Pain presented at the 16th World Congress on Pain
  • 23 Mar 2015 InMed Pharmaceuticals receives exemption from Health Canada for using phytocannabinoids for research and preclinical studies
  • 19 Mar 2015 Preclinical trials in Pain in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top